Skip to content

Divi#39;s Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill

Divi#39;s Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials.

Read More

​ Divi#39;s Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials. Divi#39;s Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish